Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

UFS shines in MBA survey
2006-10-25

Here are Prof Tienie Crous (Dean: Faculty of Economic and Management Sciences at the UFS) and Prof Helena van Zyl (Director of the UFS School of Management) with a copy of the Financial Mail.
Photo: Leonie Bolleurs

UFS shines in MBA survey
According to a recent survey published in the Financial Mail, the MBA programme presented by the School of Management at the University of the Free State (UFS) was rated jointly second best in the country by its graduates in terms of quality and standard.
The UFS MBA Programme was also rated fourth best by its graduates in terms of relevance to their business.

“I am overwhelmed and very proud that the School of Management, although we are a young school and have only been in existence for 7 (seven) years, has been rated so high by our graduandi. The School contributes in a very special way to much-needed business training in central South Africa,” said Prof Helena van Zyl, Director of the UFS School of Management.

“According to the survey, we have the lowest acceptance rate of applicants for the MBA programme, with only 33 students being accepted out of every 100 who apply.  In general, we do not compromise on quality – as stated by our slogan: Be worth more.  Given the quality of the programme, our MBA is very affordable – it offers real value for money,” said Prof van Zyl.

According to Prof van Zyl, the School of Management has had an increase the past 6 (six) months in enquiries from prospective students from Gauteng who are interested in studying the MBA programme.  “They are even prepared to travel to Bloemfontein to attend classes,” she said. 

This year Financial Mail moved away from an overall MBA ranking to a detailed consideration of subject area strengths for each business school in South Africa.  The subject Strategy offered at the UFS School of Management was rated second in the country while the subject Economics also received the same rating.

“The School of Management is the flagship of the Faculty of Economic and Management Sciences.  It gives the UFS and this faculty a standing in corporate South Africa.  This is largely due to Prof Helena van Zyl’s strategy to position the school and making it visible on a national level,” said Prof Tienie Crous, Dean: Faculty of Economic and Management Sciences at the UFS.

According to Prof Crous, the UFS School of Management provides students with opportunities to obtain first-hand experience of how big and successful companies are managed.  “For instance, our MBA students undertake an overseas study tour every year.  This year they visited amongst others the headquarters of Airbus in Toulouse, France and next year they will be visiting the headquarters of Toyota and Yamaha in Japan,” said Prof Crous.

Media release
Issued by: Lacea Loader
Media Representative
Tel:   (051) 401-2584
Cell:  083 645 2454
E-mail:  loaderl.stg@mail.uovs.ac.za
24 October 2006

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept